A new Bayesian Backtesting framework: Application to Non-Linear Mortality modeling

Melvern Leung

Supervisors: A.Prof. Athanasios Pantelous A.Prof Catherine Forbes

Econometrics and Business Statistics (Actuarial)

QFRA(2019) 26-29 June Kos Island

July 21, 2019

2 [Modeling](#page-18-0)

3 [Dynamic Linear Model - Estimation](#page-21-0)

4 [Bayesian Testing](#page-25-0)

5 [Contributions](#page-31-0)

[Background](#page-4-0) **[Motivation](#page-5-0)**

Background

• Produce a new method of backtesting specifically tiered to Longevity risk management.

[Background](#page-4-0) [Motivation](#page-5-0)

- Produce a new method of backtesting specifically tiered to Longevity risk management.
- Cast the famous Lee-Carter model and Cairns-Blake-Dowd Model in a Bayesian (non-linear) state-space form under the Poisson/Binomial Error structure.

[Background](#page-2-0) [Motivation](#page-5-0)

- Produce a new method of backtesting specifically tiered to Longevity risk management.
- Cast the famous Lee-Carter model and Cairns-Blake-Dowd Model in a Bayesian (non-linear) state-space form under the Poisson/Binomial Error structure.
- Application of the backtesting approach to compare whether the Poisson/Binomial Error structure provides a better tool for mortality modeling than the linear state-space form.

Motivation

Life annuity, deferred annuity, and variable annuity are all products that hinges on longevity risk.

[Background](#page-2-0) [Motivation](#page-8-0)

Motivation

- Life annuity, deferred annuity, and variable annuity are all products that hinges on longevity risk.
- Recently longevity risk has been exacerbated by consistent mis-estimation of predicted mortality rates and life expectancy

[Background](#page-2-0) [Motivation](#page-8-0)

Motivation

- Life annuity, deferred annuity, and variable annuity are all products that hinges on longevity risk.
- Recently longevity risk has been exacerbated by consistent mis-estimation of predicted mortality rates and life expectancy
- Bayesian Linear mortality models have been used extensively in literature as a means to provide better fit but there is an issue!

[Background](#page-2-0) [Motivation](#page-5-0)

Motivation

- Life annuity, deferred annuity, and variable annuity are all products that hinges on longevity risk.
- Recently longevity risk has been exacerbated by consistent mis-estimation of predicted mortality rates and life expectancy
- Bayesian Linear mortality models have been used extensively in literature as a means to provide better fit but there is an issue!
- Can we create a framework which determines whether a model is "good enough" to capture longevity risk? More specifically, managing longevity risk?

[Introduction](#page-2-0)

[Modeling](#page-18-0) [Dynamic Linear Model - Estimation](#page-21-0) [Bayesian Testing](#page-25-0) [Contributions](#page-31-0) [References](#page-35-0)

[Background](#page-2-0) [Motivation](#page-5-0)

The issue with Null-Hypothesis Significance-Testing (NHST)

• The question whether we want to answer

 $P(Data|H_0)$ or $P(H_0|Data)$. (1)

[Background](#page-2-0) [Motivation](#page-5-0)

The issue with Null-Hypothesis Significance-Testing (NHST)

[References](#page-35-0)

• The question whether we want to answer

$$
P(\text{Data}|\text{H}_0) \text{ or } P(\text{H}_0|\text{Data}).
$$
 (1)

• Indirect inference on the alternative as the p-value is conditional on the Null.

[Background](#page-2-0) [Motivation](#page-5-0)

The issue with Null-Hypothesis Significance-Testing (NHST)

• The question whether we want to answer

$$
P(\text{Data}|\text{H}_0) \text{ or } P(\text{H}_0|\text{Data}).
$$
 (1)

- Indirect inference on the alternative as the p-value is conditional on the Null.
- Under a Bayesian Hypothesis Testing, we are aiming to find $Pr(H_0|Data)$

[Background](#page-2-0) [Motivation](#page-5-0)

The issue with Null-Hypothesis Significance-Testing (NHST)

• The question whether we want to answer

$$
P(\text{Data}|\text{H}_0) \text{ or } P(\text{H}_0|\text{Data}).
$$
 (1)

- Indirect inference on the alternative as the p-value is conditional on the Null.
- Under a Bayesian Hypothesis Testing, we are aiming to find $Pr(H_0|Data)$
- **•** Transparency under Bayesian Hypothesis Testing

[Background](#page-2-0) [Motivation](#page-5-0)

The Bayesian Backtesting Framework

• Our new backtesting framework tries to combine both the area of Bayesian Hypothesis testing, and the Kupiec's Unconditional Coverage test. (Bayesian is used as an alternative means to Frequentist testing).

[Background](#page-2-0) [Motivation](#page-5-0)

The Bayesian Backtesting Framework

- Our new backtesting framework tries to combine both the area of Bayesian Hypothesis testing, and the Kupiec's Unconditional Coverage test. (Bayesian is used as an alternative means to Frequentist testing).
- First approach is using the Bayes Factor (B_{01})

[Background](#page-2-0) [Motivation](#page-5-0)

The Bayesian Backtesting Framework

- Our new backtesting framework tries to combine both the area of Bayesian Hypothesis testing, and the Kupiec's Unconditional Coverage test. (Bayesian is used as an alternative means to Frequentist testing).
- First approach is using the Bayes Factor (B_{01})
- **•** Second approach is using the Bayesian Likelihood Ratio test. $(BLRT₀₁)$

[Background](#page-2-0) [Motivation](#page-5-0)

The Bayesian Backtesting Framework

- Our new backtesting framework tries to combine both the area of Bayesian Hypothesis testing, and the Kupiec's Unconditional Coverage test. (Bayesian is used as an alternative means to Frequentist testing).
- First approach is using the Bayes Factor (B_{01})
- **•** Second approach is using the Bayesian Likelihood Ratio test. $(BLRT₀₁)$
- **•** Test for robustness using varying hyper-parameters.

[Background](#page-2-0) [Motivation](#page-5-0)

Bayesian Mortality Model

- Introduce the two most commonly used mortality models, Lee-Carter [\(Lee and Carter, 1992\)](#page-35-1), and the Cairns Blake Dowd (CBD) model [\(Cairns et al., 2006\)](#page-35-2).
- Casting Lee-Carter and CBD model in State-Space form.
- 2 Estimation methods, Bayesian Non-linear State-Space model, and the Bayesian linear State-Space method under Gaussian error (see [Fung et al. \(2015\)](#page-35-3); [Leung et al. \(2018\)](#page-35-4); [Pedroza \(2006\)](#page-36-0))

Notations

- age vector $x := (x_1, ..., x_n)$,
- time vector $\mathbf{t} := (t_1, ..., t_T)$
- **•** constant force of mortality assumption and we denote this by $m_{x,t}$.

$$
\mu_{x+s,t+s} = \mu_{x,t} = m_{x,t} \quad \text{for } 0 \le s < 1 \text{ and } x \in \mathbb{N}.
$$

 $D_{x,t}$ = No. of deaths, $E_{x,t}$ = central exposure

The Problem

Let the crude mortality rate be denoted as $\tilde{m}_{x,t} = \frac{D_{x,t}}{E_{x,t}}$ $\frac{D_{x,t}}{E_{x,t}}$. Let, $\mathcal{y}_{\mathsf{x},t} := \mathsf{log}(\tilde{m}_{\mathsf{x},t})$, the Lee-Carter model assumes that

$$
\mathbf{y_t} = \boldsymbol{\alpha} + \boldsymbol{\beta}\kappa_t + \boldsymbol{\varepsilon_t}, \quad \varepsilon_t \sim \mathcal{N}(\mathbf{0}, \mathbb{I}_n \sigma_{\varepsilon}^2)
$$

$$
\kappa_t = \kappa_{t-1} + \mu + \omega_t, \quad \omega_t \sim \mathcal{N}(0, \sigma_\omega^2)
$$

Let the probability of death be denoted as $\tilde{q}_{x,t} = -\log(1 - \tilde{m}_{x,t}).$ CBD Model propose to model the probability of death as,

$$
\log\left(\frac{\tilde{q}_{x,t}}{1-\tilde{q}_{x,t}}\right) = \kappa_{1,t} + \kappa_{2,t}(x-\bar{x}) + \varepsilon_{x,t}, \quad \varepsilon_{x,t} \sim N(0, \sigma_{\varepsilon}^2)
$$

$$
\begin{bmatrix} \kappa_{1,t} \\ \kappa_{2,t} \end{bmatrix} = \begin{bmatrix} \theta_1 \\ \theta_2 \end{bmatrix} + \begin{bmatrix} \kappa_{1,t-1} \\ \kappa_{2,t-1} \end{bmatrix} + \begin{bmatrix} \omega_{1,t} \\ \omega_{2,t} \end{bmatrix}, \quad \begin{bmatrix} \omega_{1,t} \\ \omega_{2,t} \end{bmatrix} \sim N(0, \Sigma),
$$

Dynamic Linear Model

Natural Exponential Family: log $(\mathsf{Pr}(\mathbf{y}|\eta))=\mathbf{y}^{\mathsf{T}}\eta-b(\eta)+c(\mathbf{y})$ Assuming that death rates $D_{\!\times\! ,t}$ follows a Poisson distribution

$$
Pr(D_{x,t} = d_{x,t} | E_{x,t}, m_{x,t}) = \frac{e^{-E_{x,t}m_{x,t}}(E_{x,t}m_{x,t})^{d_{x,t}}}{d_{x,t}!},
$$

$$
\mathsf{log}(\mathsf{Pr}(D_{x,t} = d_{x,t} | E_{x,t},m_{x,t})) = d_{x,t} \, \mathsf{log}(\mathit{E}_{x,t}m_{x,t}) - \mathit{E}_{x,t}m_{x,t} - \mathsf{log}(d_{x,t}!)
$$

If death rates $D_{x,t}$ follows a Binomial Distribution then,

$$
Pr(D_{x,t} = d_{x,t} | E_{x,t}, q_{x,t}) = {E_{x,t} \choose d_{x,t}} q_{x,t}^{d_{x,t}} (1 - q_{x,t})^{E_{x,t} - d_{x,t}}
$$

$$
log(Pr(D_{x,t=d_{x,t}} | E_{x,t}, q_{x,t})) = d_{x,t} log(\frac{q_{x,t}}{1 - q_{x,t}}) + E_{x,t} log(1 - q_{x,t}) + log(\frac{E_{x,t}}{d_{x,t}})
$$

Non-Linear Mortality Model

Under Lee-Carter Poisson Model

$$
(D_{x,t}|E_{x,t}m_{x,t}) \sim \frac{e^{-E_{x,t}m_{x,t}}(E_{x,t}m_{x,t})^{d_{x,t}}}{d_{x,t}!}
$$

$$
log(m_{x,t}) = (\alpha_x + \beta_x \kappa_t),
$$

$$
\kappa_t = \kappa_{t-1} + \mu + \omega_t,
$$

Under CBD Binomial Model,

$$
(D_{x,t} | E_{x,t}, q_{x,t}) \sim \begin{pmatrix} E_{x,t} \\ d_{x,t} \end{pmatrix} q_{x,t}^{d_{x,t}} (1 - q_{x,t})^{E_{x,t} - d_{x,t}}
$$

\n
$$
\log \begin{pmatrix} \frac{q_{x,t}}{1 - q_{x,t}} \end{pmatrix} = \kappa_{1,t} + \kappa_{2,t} (x - \bar{x}),
$$

\n
$$
\begin{bmatrix} \kappa_{1,t} \\ \kappa_{2,t} \end{bmatrix} = \begin{bmatrix} \theta_1 \\ \theta_2 \end{bmatrix} + \begin{bmatrix} \kappa_{1,t-1} \\ \kappa_{2,t-1} \end{bmatrix} + \begin{bmatrix} \omega_{1,t} \\ \omega_{2,t} \end{bmatrix}, \quad \begin{bmatrix} \omega_{1,t} \\ \omega_{2,t} \end{bmatrix} \sim N(\mathbf{0}, \Sigma).
$$

Bayesian Non-Linear State-Space

Algorithm: We cast the mortality models in state-space form, and perform MCMC sampling of the model parameters. In the Bayesian setting, our aim is to conduct inference on the joint posterior density

 $\pi(\kappa_{1:t_{\mathcal{T}}}, \Psi \vert \mathbf{y}_{1:t_{\mathcal{T}}}),$

using Gibbs sampling [\(Geman and Geman, 1984\)](#page-35-5),

$$
\pi(\kappa_{1:t_{\mathcal{T}}},\Psi|\mathbf{y}_{1:t_{\mathcal{T}}})\propto \pi(\Psi|\kappa_{1:t_{\mathcal{T}}},\mathbf{y}_{1:t_{\mathcal{T}}})\; \pi(\kappa_{1:t_{\mathcal{T}}}|\Psi,\mathbf{y}_{1:t_{\mathcal{T}}}) \qquad (2)
$$

1 Initialize $\Psi = \Psi^{(0)}$

2 For $i = 1, ..., M$.

- \bullet sample $\kappa^{(i)}$ from $\pi(\kappa_{1:t_{\mathcal{T}}}|\Psi^{(i-1)},\mathbf{y}_{1:t_{\mathcal{T}}})$ Extended Kalman Filter
- \textbf{a} sample $\boldsymbol{\Psi}^{(i)}$ from $\pi(\boldsymbol{\Psi}|\boldsymbol{\kappa}_{1:t_{\mathcal{T}}}^{(i)}, \boldsymbol{\mathsf{y}}_{1:t_{\mathcal{T}}})$ MCMC

Figure 1: Age 50 UK

Bayesian Linear Bayesian Non-Linear

Figure 3: Age 80 AUS

 0.016 0.012 동
맡 _{0.009}. **Bayesian Linear** Bayesian Non-Linear $0.006 -$ 1950 1960 1970 1980 1990 2000 2010 Year

Figure 2: Age 55 UK

Figure 4: Age 85 AUS

Liability calculation

Let the survival rate of a person aged x surviving for the next t years be found by,

$$
S_{\scriptscriptstyle \times}(t) = \prod_{i=1}^t (1 - q_{{\scriptscriptstyle \times}+i, t_1+i}) \tag{3}
$$

 $/22$

Assume now we are obligated to pay \$1 to a person currently aged x for the next T years. Let the price of a zero coupon bond which matures in t years be denoted as $P(0, t)$, we then have the liability for a \$1 annuity to a person aged x over T years to be,

$$
L_x(\mathcal{T}) = \sum_{t=1}^T P(0, t) S_x(t),
$$

\n
$$
L_x^{\text{Realised}}(\mathcal{T}) = \sum_{t=1}^T P(0, t) S_x^{\text{Realised}}(t),
$$

\n
$$
L_x^{\text{Upper}}(\mathcal{T}) = \sum_{t=1}^T P(0, t) S_x(t), \text{Upper 99% Quantile for } S_x(t)
$$

$$
\text{``Hit'' } \mathcal{I}_x(\mathcal{T}) = \begin{cases} 0, & \text{for } \mathsf{L}_x^{\mathsf{Realised}}(\mathcal{T}) < \mathsf{L}_x^{\mathsf{upper}}(\mathcal{T}) \\ 1, & \text{for } \mathsf{L}_x^{\mathsf{Realised}}(\mathcal{T}) > \mathsf{L}_x^{\mathsf{upper}}(\mathcal{T}) \end{cases}
$$

produce 99% upper bound of
$$
L_x(T)
$$
 denote as $L_x^{\text{Upper}}(T)$

\n
$$
\downarrow
$$
\n
$$
L_x^{\text{Upper}}(T) < L_x^{\text{Bealised}}(T)
$$
\n
$$
L_x^{\text{Upper}}(T) > L_x^{\text{Bealised}}(T)
$$

[Introduction](#page-2-0) [Modeling](#page-18-0) [Dynamic Linear Model - Estimation](#page-21-0) [Bayesian Testing](#page-25-0) [Contributions](#page-31-0)

Here we apply a 5-year forecast horizon and obtain lower and upper bounds on $L_{x}(T)$ based on the Linear and Non-Linear estimation methods. The $L_{\mathsf{x}}^{\mathsf{Upper}}(\mathcal{T})$, represents $L_{\mathsf{x}}(\mathcal{T})$ calculated at the 99% quantile of our mortality forecasts

[Introduction](#page-2-0) [Modeling](#page-18-0) [Bayesian Testing](#page-25-0) [Contributions](#page-31-0) [References](#page-35-0)

Liability Bounds

18 / 22

Backtesting VaR using Bayesian Decision Theory

Model 1: Null Hypothesis, 'hits' occur with probability $\alpha = \alpha^* = 0.01$.

$$
L(\mathcal{I}|\alpha) = \alpha^{m_1} (1 - \alpha)^{m - m_1},\tag{4}
$$

where m represents the sample size and m_1 represents the number of hits.

Model 2: Alternative Hypothesis, 'hits' occur with probability different from 0.01.

Given non-informative priors

$$
\pi(\alpha) = \begin{cases} 1 & \text{if } \alpha = \alpha^*, \\ \text{Beta}(0.5, 0.5), & \text{if } \alpha \neq \alpha^*. \end{cases}
$$

$$
BF_{01} = \frac{(\alpha^*)^{m_1}(1 - \alpha^*)^{m - m_1}}{B(m_1 + 0.5, m + 0.5)} > 1
$$

Table of Results

Table 1: Bayes Factor under Bayesian Linear and Bayesian Non-Linear methods

Major Contributions

• Create a new Framework for backtesting Mortality models tailored to longevity risk.

Major Contributions

- **Create a new Framework for backtesting Mortality models** tailored to longevity risk.
- Cast two mortality models (LC and CBD) in non-linear state-space form.

Major Contributions

- **•** Create a new Framework for backtesting Mortality models tailored to longevity risk.
- Cast two mortality models (LC and CBD) in non-linear state-space form.
- Compared the result to show that the non-linear state-space form succeeds the linear case under our backtesting framework.

[Introduction](#page-2-0) [Modeling](#page-18-0) [Bayesian Testing](#page-25-0) [Contributions](#page-31-0) [References](#page-35-0)

The End

Cairns, A., Blake, D., and Dowd, K. (2006). A two-factor model for stochastic mortality with parameter uncertainty: Theory and calibration. Journal of Risk and Insurance, 73(4):687–718.

- Fung, M. C., Ignatieva, K., and Sherris, M. (2015). Managing systematic mortality risk in life annuities: An application of longevity derivatives. UNSW Business School Research Paper, (20015ACTL04).
- Geman, S. and Geman, D. (1984). Stochastic relaxation, gibbs distributions, and the bayesian restoration of images. Pattern Analysis and Machine Intelligence, IEEE Transactions on, (6):721–741.
- Lee, R. D. and Carter, L. R. (1992). Modeling and forecasting U.S. mortality. Journal of the American Statistical Association, 87:659–675.
- Leung, M., Fung, M. C., and O'Hare, C. (2018). A comparative

study of pricing approaches for longevity instruments. *Insurance:* Mathematics and Economics, 82:95–116.

Pedroza, C. (2006). A bayesian forecasting model: predicting us male mortality. Biostatistics, 7(4):530-550.